Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study

@inproceedings{Masuda2012AbstractPE,
  title={Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study},
  author={Norikazu Masuda and Daigo Yamamoto and Nobuaki Sato and Yasuaki Sagara and Yutaka Yamamoto and Mitsue Saito and Hiroji Iwata and Shoji Oura and Junichiro Watanabe and Katsumasa Kuroi},
  year={2012}
}
Introduction: Circulating tumor cell (CTC) has been reported as a predictive marker of prognosis and treatment response in metastatic breast cancer by comparing CTC count prior to and after treatment. However, most of previous reports were based on retrospective studies and still controversial. We prospectively evaluated CTC as a marker of prognosis and treatment efficacy in a randomized multi-center phase III study in HER2 negative metastatic breast cancer patients (pts) in Japan. Methods: Pts… CONTINUE READING